特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
940310

呼吸器用医薬品の世界市場:2027年までの展望

Global Respiratory Drugs Market Outlook 2027

出版日: | 発行: Research Nester | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
呼吸器用医薬品の世界市場:2027年までの展望
出版日: 2020年05月01日
発行: Research Nester
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の呼吸器用医薬品市場は、2019年から2027年まで6.0%のCAGRで成長を続け255億ドルに達する見通しです。

当レポートは、世界の呼吸器用医薬品市場を調査したもので、市場の概要、種類別、剤形別、疾患別、投与形態別、投与経路別、流通チャネル別、地域別の市場分析、企業プロファイル、パイプライン分析などの情報を提供しています。

目次

第1章 レポートの概要

第2章 イントロダクション

  • 市場の構造
  • 市場の定義
  • 市場区分
  • 市場のスナップショット
  • 疫学分析
    • 喘息
    • 慢性閉塞性肺疾患
    • 嚢胞性線維症
    • 肺高血圧症
    • アレルギー性鼻炎
    • 特発性肺線維症
  • 市場の力学
    • 成長促進要因
    • 成長阻害要因
    • トレンド
    • 機会

第3章 市場分析:種類別

  • イントロダクション
  • 市場規模と予測
    • 抗喘息薬とCOPD治療薬
    • 咳と風邪の常備薬
    • 肺高血圧症治療薬
    • 特発性肺線維症治療薬

第4章 市場分析:剤型別

  • イントロダクション
  • 市場規模と予測
    • 乾燥粉末
    • タブレット、カプセル
    • スプレー
    • シロップ、液剤

第5章 市場分析:疾患別

  • イントロダクション
  • 市場規模と予測
    • 喘息
    • 慢性閉塞性肺疾患
    • 嚢胞性線維症
    • 肺高血圧症
    • アレルギー性鼻炎
    • 特発性肺線維症
    • その他

第6章 市場分析:投与形態別

  • イントロダクション
  • 市場規模と予測
    • 単剤投与
    • 併用投与

第7章 市場分析:投与経路別

  • イントロダクション
  • 市場規模と予測
    • 吸入
    • 経口
    • 注射

第8章 市場分析:流通チャネル別

  • イントロダクション
  • 市場規模と予測
    • オンライン
    • オフライン

第9章 市場分析:地域別

  • イントロダクション
  • 市場規模と予測
    • 北米
    • ラテンアメリカ
    • 欧州
    • アジア太平洋
    • 中東・アフリカ

第10章 北米市場の分析と予測

  • イントロダクション
    • 国別
    • 種類別
    • 剤形別
    • 疾患別
    • 投与形態別
    • 投与経路別
    • 流通チャネル別

第11章 ラテンアメリカ市場の分析と予測

  • イントロダクション
    • 国別
    • 種類別
    • 剤形別
    • 疾患別
    • 投与形態別
    • 投与経路別
    • 流通チャネル別

第12章 欧州市場の分析と予測

  • イントロダクション
    • 国別
    • 種類別
    • 剤形別
    • 疾患別
    • 投与形態別
    • 投与経路別
    • 流通チャネル別

第13章 アジア太平洋市場の分析と予測

  • イントロダクション
    • 国別
    • 種類別
    • 剤形別
    • 疾患別
    • 投与形態別
    • 投与経路別
    • 流通チャネル別

第14章 中東・アフリカ市場の分析と予測

  • イントロダクション
    • 国別
    • 種類別
    • 剤形別
    • 疾患別
    • 投与形態別
    • 投与経路別
    • 流通チャネル別

第15章 企業プロファイル

  • ASTRAZENECA PLC
    • 概観
    • 製品タイプ/サービス提供
    • 主な動き
    • SWOT分析
  • FIBROGEN、INC
    • 概観
    • 製品タイプ/サービス提供
    • SWOT分析
  • NOVARTIS INTERNATIONAL AG
    • 概観
    • 製品タイプ/サービス提供
    • 主な動き
    • SWOT分析
  • ABBOTT LABORATORIES
    • 概観
    • 製品タイプ/サービス提供
    • SWOT分析
  • GLAXOSMITHKLINE PLC
    • 概観
    • 製品タイプ/サービス提供
    • SWOT分析
  • F. HOFFMANN-LA ROCHE AG
    • 概観
    • 製品タイプ/サービス提供
    • 主な動き
    • SWOT分析
  • MERCK&CO.,INC
    • 概観
    • 製品タイプ/サービス提供
    • 戦略
    • 主な動き
    • SWOT分析
  • SUNOVION PHARMACEUTICALS INC
    • 概観
    • 製品タイプ/サービス提供
    • SWOT分析

第16章 パイプライン分析

  • 抗喘息薬とCOPD薬
    • 長時間作用型ベータアゴニスト(LABA)
    • 長時間作用型ムスカリン性拮抗薬(ラマ)
    • コルチコステロイド
    • ロイコトリエン
    • キサンチン
  • 咳と風邪の常備薬
    • 鎮痛剤
  • 抗ヒスタミン薬
  • 充血除去剤
  • 興奮剤
  • 肺高血圧症
    • エンドセリン受容体拮抗薬
    • 抗凝固薬
  • 利尿薬
    • 可溶性グアニル酸シクラーゼ(SGC)刺激剤
  • 特発性肺線維症治療薬
    • ピルフェニドン
    • ニンテダニブ

第17章 略語

目次

COVID-19 update included

The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

Respiratory disorders mainly consist of ailments affecting the lungs such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory infections, chronic bronchitis and several others.. These respiratory illnesses can be caused by a number of factors, some of them consisting of genetics, environment, and occupation as well as ageing. The market for respiratory drugs is anticipated to grow at a CAGR of 6.0% over the forecast period, i.e., 2019-2027. Further, the market is predicted to attain a significant market value of about USD 25,500 million by the end of 2027. Innovations in the healthcare industry are resulting in increasing research and development in the area of respiratory drugs. On the back of these factors, the market for respiratory drugs is anticipated to observe a significantly high growth in the next few years.

The market for respiratory drugs is segmented by drug, by formulation, by disease, by administration, by drug delivery, by distribution channel and by region. On the basis of disease, the market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary hypertension, allergic rhinitis, idiopathic pulmonary fibrosis and others. The segment for asthma is predicted to attain the largest market value of about USD 8,500 million by the end of 2027 and grow at the highest CAGR over the forecast period. A report by the Centers for Disease Control and Prevention (CDC) stated that 1 among every 13 people is estimated to suffer from asthma and adult women are more prone to this condition as compared to adult men. This can explain the growth of this segment in the coming years.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The largest market share was held by the market in North America, with a share of 40% in 2019. The market in this region is further estimated to continue holding the largest share over the forecast period. Moreover, this is closely followed by the market in Asia Pacific on the back of the rising developments and increasing innovations in the healthcare industry in the Asia Pacific region which account for the development of a higher number of respiratory drugs as compared with other regions.

Some of the key industry leaders in the global respiratory drugs market are: AstraZeneca, Fibrogen Inc., Novartis International AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-la Roche AG, Merck & Co. Inc. and Sunovion Pharmaceuticals Inc.

TABLE OF CONTENTS

1. Report Overview

  • 1.1. Global Respiratory Drugs Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
    • 1.6.1. Primary Research
    • 1.6.2. Secondary Research
    • 1.6.3. Market Evaluation & Forecasting Methodology

2. Introduction to the Respiratory Drugs Market

  • 2.1. Respiratory Drugs Market Structure
  • 2.2. Respiratory Drugs Market Definition
  • 2.3. Global Respiratory Drugs Market Taxonomy
  • 2.4. Global Respiratory Drugs Market Snapshot
  • 2.5. Epidemiology Analysis

ASTHMA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CYSTIC FIBROSIS

PULMONARY HYPERTENSION

ALLERGIC RHINITIS

IDIOPATHIC PULMONARY FIBROSIS

  • 2.6. Global Respiratory Drugs Market Dynamics
    • 2.6.1. Global Respiratory Drugs Market: Driver
    • 2.6.2. Global Respiratory Drugs Market: Restraints
    • 2.6.1. Global Respiratory Drugs Market: Trends
    • 2.6.1. Global Respiratory Drugs Market: Opportunities

3. Global Respiratory Drugs Market, By Drug Type, 2019-2027

  • 3.1. Introduction
  • 3.2. Global Respiratory Drugs Market Size and Forecast, By Drug Type
    • 3.2.1. Anti-Asthmatics & COPD Drug Segment
    • 3.2.2. Cough & Cold Preparations Drug Segment
    • 3.2.3. Pulmonary Hypertension Segment
    • 3.2.4. Idiopathic Pulmonary Fibrosis Segment

4. Global Respiratory Drugs Market, By Formulation, 2019-2027

  • 4.1. Introduction
  • 4.2. Global Respiratory Drugs Market Size and Forecast, By Formulation
    • 4.2.1. Dry Powder Segment
    • 4.2.2. Tablets & Capsules Segment
    • 4.2.3. Sprays Segment
    • 4.2.4. Syrups & Solutions Segment

5. Global Respiratory Drugs Market, By Disease, 2019-2027

  • 5.1. Introduction
  • 5.2. Global Respiratory Drugs Market Size and Forecast, By Disease
    • 5.2.1. Asthma Segment
    • 5.2.2. Chronic Obstructive Pulmonary Disease Segment
    • 5.2.3. Cystic Fibrosis Segment
    • 5.2.4. Pulmonary Hypertension Segment
    • 5.2.5. Allergic Rhinitis Segment
    • 5.2.6. Idiopathic Pulmonary Fibrosis Segment
    • 5.2.7. Others Segment

6. Global Respiratory Drugs Market, By Administration, 2019-2027

  • 6.1. Introduction
  • 6.2. Global Respiratory Drugs Market Size and Forecast, By Administration
    • 6.2.1. Stand Alone Drugs Segment
    • 6.2.2. Combination Drugs Segment

7. Global Respiratory Drugs Market, By Drug Delivery, 2019-2027

  • 7.1. Introduction
  • 7.2. Global Respiratory Drugs Market Size and Forecast, By Drug Delivery
    • 7.2.1. Inhalational Segment
    • 7.2.2. Oral Segment
    • 7.2.3. Injection Segment

8. Global Respiratory Drugs Market, By Distribution Channel, 2019-2027

  • 8.1. Introduction
  • 8.2. Global Respiratory Drugs Market Size and Forecast, By Distribution Channel
    • 8.2.1. Online Segment
    • 8.2.2. Offline Segment

9. Global Respiratory Drugs Market, By Region, 2019-2027

  • 9.1. Introduction
  • 9.2. Global Respiratory Drugs Market Size and Forecast, By Region
    • 9.2.1. North America
    • 9.2.2. Latin America
    • 9.2.3. Europe
    • 9.2.4. Asia Pacific
    • 9.2.5. Middle East and Africa

10. North America Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 10.1. Introduction
    • 10.1.1. North America
  • 10.2. North America Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 10.3. North America Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 10.4. North America Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 10.5. North America Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 10.6. North America Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 10.7. North America Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 10.8. North America Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

11. Latin America Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 11.1. Introduction
    • 11.1.1. Latin America
  • 11.2. Latin America Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 11.3. Latin America Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 11.4. Latin America Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 11.5. Latin America Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 11.6. Latin America Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 11.7. Latin America Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 11.8. Latin America Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

12. Europe Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 12.1. Introduction
    • 12.1.1. Europe
  • 12.2. Europe Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 12.3. Europe Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 12.4. Europe Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 12.5. Europe Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 12.6. Europe Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 12.7. Europe Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 12.8. Europe Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

13. Asia Pacific Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 13.1. Introduction
    • 13.1.1. Asia Pacific
  • 13.2. Asia Pacific Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 13.3. Asia Pacific Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 13.4. Asia Pacific Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 13.5. Asia Pacific Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 13.6. Asia Pacific Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 13.7. Asia Pacific Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 13.8. Asia Pacific Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

14. Middle East & Africa Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 14.1. Introduction
    • 14.1.1. MEA
  • 14.2. MEA Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 14.3. MEA Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 14.4. MEA Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 14.5. MEA Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 14.6. MEA Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 14.7. MEA Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 14.8. MEA Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

15. Company Profile

  • 15.1. ASTRAZENECA PLC
    • 15.1.1. Overview
    • 15.1.2. Product Type/Service Offerings
    • 15.1.3. Key Developments
    • 15.1.4. SWOT ANALYSIS
  • 15.2. FIBROGEN, INC
    • 15.2.1. Overview
    • 15.2.2. Product Type/Service Offerings
    • 15.2.3. SWOT Analysis
  • 15.3. NOVARTIS INTERNATIONAL AG
    • 15.3.1. Overview
    • 15.3.2. Product Type/Service Offerings
    • 15.3.3. Key Developments
    • 15.3.4. SWOT ANALYSIS
  • 15.4. ABBOTT LABORATORIES
    • 15.4.1. Overview
    • 15.4.2. Product Type/Service Offerings
    • 15.4.3. SWOT Analysis
  • 15.5. GLAXOSMITHKLINE PLC
    • 15.5.1. Overview
    • 15.5.2. Product Type/Service Offerings
    • 15.5.3. SWOT Analysis
  • 15.6. F. HOFFMANN-LA ROCHE AG
    • 15.6.1. Overview
    • 15.6.2. Product Type/Service Offerings
    • 15.6.3. Key Developments
    • 15.6.4. SWOT Analysis
  • 15.7. MERCK & CO., INC
    • 15.7.1. Overview
    • 15.7.2. Product Type/Service Offerings
    • 15.7.3. Strategy (s)
    • 15.7.4. Key Developments
    • 15.7.5. SWOT Analysis
  • 15.8. SUNOVION PHARMACEUTICALS INC
    • 15.8.1. Overview
    • 15.8.2. Product Type/Service Offerings
    • 15.8.3. SWOT Analysis

16. Respiratory Drugs Pipeline Analysis

  • 16.1. ANTI-ASTHMATICS AND COPD DRUG
    • 16.1.1. LONG-ACTING BETA-AGONISTS (LABA)

Study Description

Study Design

    • 16.1.2. LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA)

Study Description

Study Design

Study Description

Study Design

    • 16.1.3. CORTICOSTEROIDS

Study Description

Study Design

Study Description

Study Design

Study Description

Study Design

    • 16.1.4. LEUKOTRIENE

Study Description

Study Design

Study Description

Study Design

    • 16.1.5. XANTHINES

Study Description

Study Design

  • 16.2. COUGH AND COLD PREPARATIONS DRUG
    • 16.2.1. ANTITUSSIVES

Study Description

Study Design

Study Description

Study Design

  • 16.3. ANTIHISTAMINES

Study Description

Study Design

Study Description

Study Design

  • 16.4. DECONGESTANTS

Study Description

Study Design

Study Description

Study Design

  • 16.5. EXPECTORANTS

Study Description

Study Design

Study Description

Study Design

  • 16.6. PULMONARY HYPERTENSION
    • 16.6.1. ENDOTHELIN RECEPTOR ANTAGONISTS

Study Description

Study Design

    • 16.6.2. ANTICOAGULANTS

Study Description

Study Design

Study Description

Study Design

  • 16.7. DIURETICS

Study Description

Study Design

Study Description

Study Design

    • 16.7.1. SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR

Study Description

Study Design

Study Description

Study Design

  • 16.8. IDIOPATHIC PULMONARY FIBROSIS
    • 16.8.1. PIRFENIDONE

Study Description

Study Design

Study Description

Study Design

    • 16.8.2. NINTEDANIB

Study Description

Study Design

Study Description

Study Design

17. Acronyms

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.